PRIMA-4TB
The Usage of Rifapentine, Isoniazid, Pyrazinamide, and Moxifloxacin Combination for 4 months for Drug-Sensitive Tuberculosis Patients in Indonesia
Background
One of the challenges in TB treatment is patient compliance due to the long duration of treatment. Shorter duration regimens can reduce TB incidence and mortality by 27% and 25% by 2050. In 2022, WHO recommends a four-month 2HPMZ/2HPM scheme. Therefore, operational research was conducted to evaluate the effectiveness, acceptability, and safety of the HPMZ strategy.
Information
Use of Rifapentine, Isoniazid, Pyrazinamide, and Moxifloxacin Combination for 4 months for Drug-Sensitive Tuberculosis Patients in Indonesia
Type of Study
Operational Study
Topic
Tuberculosis
Collaborator
Kementerian Kesehatan Republik Indonesia
